17 results on '"Jing-xu Sun"'
Search Results
2. The Efficacy and Safety of Celecoxib in Addition to Standard Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Author
-
Shi-Yu Ye, Jia-Yi Li, Teng-Hui Li, Yong-Xi Song, Jing-Xu Sun, Xiao-Wan Chen, Jun-Hua Zhao, Yuan Li, Zhong-Hua Wu, Peng Gao, and Xuan-Zhang Huang
- Subjects
cancer therapy ,meta-analysis ,celecoxib ,survival ,local control ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
The purpose of this meta-analysis was to evaluate the efficacy and safety of celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, in addition to standard anticancer therapy. Randomized controlled trials (RCTs) that evaluated the efficacy and safety of celecoxib-combined cancer therapy were systematically searched in PubMed and Embase databases. The endpoints were overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), objective response rate (ORR), disease control rate (DCR), pathological complete response (pCR), and adverse events (AEs). The results of 30 RCTs containing 9655 patients showed limited benefits in celecoxib-combined cancer therapy. However, celecoxib-combined palliative therapy prolonged PFS in epidermal growth factor receptor (EGFR) wild-type patients (HR = 0.57, 95%CI = 0.35–0.94). Moreover, despite a slight increase in thrombocytopenia (RR = 1.35, 95%CI = 1.08–1.69), there was no increase in other toxicities. Celecoxib combined with adjuvant therapy indicated a better OS (HR = 0.850, 95%CI = 0.725–0.996). Furthermore, celecoxib plus neoadjuvant therapy improved the ORR in standard cancer therapy, especially neoadjuvant therapy (overall: RR = 1.13, 95%CI = 1.03–1.23; neoadjuvant therapy: RR = 1.25, 95%CI = 1.09–1.44), but not pCR. Our study indicated that adding celecoxib to palliative therapy prolongs the PFS of EGFR wild-type patients, with good safety profiles. Celecoxib combined with adjuvant therapy prolongs OS, and celecoxib plus neoadjuvant therapy improves the ORR. Thus, celecoxib-combined cancer therapy may be a promising therapy strategy.
- Published
- 2022
- Full Text
- View/download PDF
3. Author Correction: Non-coding RNAs participate in the regulatory network of CLDN4 via ceRNA mediated miRNA evasion
- Author
-
Yong-xi Song, Jing-xu Sun, Jun-hua Zhao, Yu-chong Yang, Jin-xin Shi, Zhong-hua Wu, Xiao-wan Chen, Peng Gao, Zhi-feng Miao, and Zhen-ning Wang
- Subjects
Science - Published
- 2021
- Full Text
- View/download PDF
4. Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients
- Author
-
Xuan-Zhang Huang, Peng Gao, Yong-Xi Song, Yan Xu, Jing-Xu Sun, Xiao-Wan Chen, Jun-Hua Zhao, and Zhen-Ning Wang
- Subjects
antibiotics ,immune checkpoint inhibitors ,immunotherapy ,overall survival ,progression-free survival ,Immunologic diseases. Allergy ,RC581-607 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
The gut microbiota plays a critical role in the anti-tumor immune response. There is increasing data showing that antibiotics (ATBs) change the composition of the gut microbiota and affect the efficacy of immune checkpoint inhibitors (ICIs). However, this is the first meta-analysis to evaluate the association between ATB use and ICI efficacy in cancer patients to provide a better understanding of the strength of this association. We performed a literature search for relevant studies that evaluated the relationship between ATB use and ICI efficacy using the PubMed, Embase, and conference databases. The primary outcomes consisted of overall survival (OS) and progression-free survival (PFS) measured by hazard ratios (HR) and corresponding 95% confidence intervals (CI). Subgroup and sensitivity analyses were also performed. A total of 19 eligible studies comprising 2,740 cancer patients treated with ICIs were included in the analysis. Our results indicated that ATB use was negatively associated with OS in cancer patients (HR = 2.37; 95% CI = 2.05–2.75; P
- Published
- 2019
- Full Text
- View/download PDF
5. Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study
- Author
-
Peng Gao, Xuan-zhang Huang, Yong-xi Song, Jing-xu Sun, Xiao-wan Chen, Yu Sun, Yu-meng Jiang, and Zhen-ning Wang
- Subjects
Colon cancer ,Stage III ,Timing of adjuvant chemotherapy ,Postoperative complications ,SEER-Medicare program ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background There is no consensus regarding the optimal time to initiate adjuvant chemotherapy after surgery for stage III colon cancer, and the relevant postoperative complications that cause delays in adjuvant chemotherapy are unknown. Methods Eligible patients aged ≥66 years who were diagnosed with stage III colon cancer from 1992 to 2008 were identified using the linked Surveillance, Epidemiology, and End Results-Medicare database. Kaplan-Meier analysis and a Cox proportional hazards model were utilized to evaluate the impact of the timing of adjuvant chemotherapy on overall survival (OS). Results A total of 18,491 patients were included. Delayed adjuvant chemotherapy was associated with worse OS (9–12 weeks: hazard ratio [HR] = 1.222, 95% confidence interval [CI] = 1.063–1.405; 13–16 weeks: HR = 1.252, 95% CI = 1.041–1.505; ≥ 17 weeks: HR = 1.969, 95% CI = 1.663–2.331). The efficacies of adjuvant chemotherapy within 5–8 weeks and ≤4 weeks were similar (HR = 1.045, 95% CI = 0.921–1.185). Compared with the non-chemotherapy group, chemotherapy initiated at ≥21 weeks did not significantly improve OS (HR = 0.882, 95% CI = 0.763–1.018). Patients with postoperative complications, particularly cardiac arrest, ostomy infection, shock, and septicemia, had a significantly higher risk of a 4- to 11-week delay in adjuvant chemotherapy (p
- Published
- 2018
- Full Text
- View/download PDF
6. Non-coding RNAs participate in the regulatory network of CLDN4 via ceRNA mediated miRNA evasion
- Author
-
Yong-xi Song, Jing-xu Sun, Jun-hua Zhao, Yu-chong Yang, Jin-xin Shi, Zhong-hua Wu, Xiao-wan Chen, Peng Gao, Zhi-feng Miao, and Zhen-ning Wang
- Subjects
Science - Abstract
Non-coding RNAs can modify the expression of proteins in cancer networks. Here the authors reveal a regulatory network in gastric cancer whereby claudin-4 expression is reduced by specific miRNAs, which are in turn bound by specific lncRNAs acting as competing endogenous RNAs (ceRNAs), resulting in increased claudin-4 expression.
- Published
- 2017
- Full Text
- View/download PDF
7. Regulatory Roles of Non-Coding RNAs in Colorectal Cancer
- Author
-
Jun Wang, Yong-Xi Song, Bin Ma, Jia-Jun Wang, Jing-Xu Sun, Xiao-Wan Chen, Jun-Hua Zhao, Yu-Chong Yang, and Zhen-Ning Wang
- Subjects
non-coding RNAs ,colorectal cancer ,dysregulation ,biomarkers ,targets ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Non-coding RNAs (ncRNAs) have recently gained attention because of their involvement in different biological processes. An increasing number of studies have demonstrated that mutations or abnormal expression of ncRNAs are closely associated with various diseases including cancer. The present review is a comprehensive examination of the aberrant regulation of ncRNAs in colorectal cancer (CRC) and a summary of the current findings on ncRNAs, including long ncRNAs, microRNAs, small interfering RNAs, small nucleolar RNAs, small nuclear RNAs, Piwi-interacting RNAs, and circular RNAs. These ncRNAs might become novel biomarkers and targets as well as potential therapeutic tools for the treatment of CRC in the near future and this review may provide important clues for further research on CRC and for the selection of effective therapeutic targets.
- Published
- 2015
- Full Text
- View/download PDF
8. DDIT4 licenses only healthy cells to proliferate during injury-induced metaplasia
- Author
-
Zhenning Wang, Kai Wen Tang, Junhua Zhao, Jing Xu Sun, Mahliyah Adkins-Threats, Jason C. Mills, Zhi Feng Miao, Xin Wang, and Min Jiao Pang
- Subjects
DNA damage ,Carcinogenesis ,Cell Culture Techniques ,mTORC1 ,Biology ,medicine.disease_cause ,Article ,Mice ,Metaplasia ,medicine ,Animals ,Humans ,Mitosis ,Cell Proliferation ,Chief Cells, Gastric ,Hepatology ,Stomach ,Gastroenterology ,Gastric chief cell ,Mice, Inbred C57BL ,medicine.anatomical_structure ,Cancer research ,Immunohistochemistry ,medicine.symptom ,Transcription Factors - Abstract
Background and Aims In stomach, metaplasia can arise from differentiated chief cells that become mitotic via paligenosis, a stepwise program. In paligenosis, mitosis initiation requires reactivation of the cellular energy hub mTORC1 after initial mTORC1 suppression by DNA damage induced transcript 4 (DDIT4 aka REDD1). Here, we use DDIT4-deficient mice and human cells to study how metaplasia increases tumorigenesis risk. Methods A tissue microarray of human gastric tissue specimens was analyzed by immunohistochemistry for DDIT4. C57BL/6 mice were administered combinations of intraperitoneal injections of high-dose tamoxifen (TAM) to induce spasmolytic polypeptide-expressing metaplasia (SPEM) and rapamycin to block mTORC1 activity, and N-methyl-N-nitrosourea (MNU) in drinking water to induce spontaneous gastric tumors. Stomachs were analyzed for proliferation, DNA damage, and tumor formation. CRISPR/Cas9-generated DDIT4−/− and control human gastric cells were analyzed for growth in vitro and in xenografts with and without 5-fluorouracil (5-FU) treatment. Results DDIT4 was expressed in normal gastric chief cells in mice and humans and decreased as chief cells became metaplastic. Paligenotic Ddit4−/− chief cells maintained constitutively high mTORC1, causing increased mitosis of metaplastic cells despite DNA damage. Lower DDIT4 expression correlated with longer survival of patients with gastric cancer. 5-FU–treated DDIT4−/− human gastric epithelial cells had significantly increased cells entering mitosis despite DNA damage and increased proliferation in vitro and in xenografts. MNU-treated Ddit4−/− mice had increased spontaneous tumorigenesis after multiple rounds of paligenosis induced by TAM. Conclusions During injury-induced metaplastic proliferation, failure of licensing mTORC1 reactivation correlates with increased proliferation of cells harboring DNA damage, as well as increased tumor formation and growth in mice and humans.
- Published
- 2020
9. A Metformin-Responsive Metabolic Pathway Controls Distinct Steps in Gastric Progenitor Fate Decisions and Maturation
- Author
-
Yan Kefalov, Jing Xu Sun, Joseph Burclaff, Zheng He, Zhi Feng Miao, Jason C. Mills, Zhenning Wang, Luciana H. Osaki, and Mahliyah Adkins-Threats
- Subjects
mTORC1 ,Biology ,AMP-Activated Protein Kinases ,Article ,03 medical and health sciences ,Kruppel-Like Factor 4 ,Mice ,0302 clinical medicine ,Genetics ,medicine ,Animals ,Progenitor cell ,030304 developmental biology ,Progenitor ,0303 health sciences ,Activator (genetics) ,Stem Cells ,Stomach ,AMPK ,Cell Biology ,Metformin ,Cell biology ,KLF4 ,Molecular Medicine ,Stem cell ,030217 neurology & neurosurgery ,Metabolic Networks and Pathways ,medicine.drug - Abstract
Cellular metabolism plays important functions in dictating stem cell behaviors, although its role in stomach epithelial homeostasis has not been evaluated in depth. Here, we show that the energy sensor AMP kinase (AMPK) governs gastric epithelial progenitor differentiation. Administering the AMPK activator metformin decreases epithelial progenitor proliferation and increases acid-secreting parietal cells (PCs) in mice and organoids. AMPK activation targets Kruppel-like factor 4 (KLF4), known to govern progenitor proliferation and PC fate choice, and PGC1α, which we show controls PC maturation after their specification. PC-specific deletion of AMPKα or PGC1α causes defective PC maturation, which could not be rescued by metformin. However, metformin treatment still increases KLF4 levels and suppresses progenitor proliferation. Thus, AMPK activates KLF4 in progenitors to reduce self-renewal and promote PC fate, whereas AMPK-PGC1α activation within the PC lineage promotes maturation, providing a potential suggestion for why metformin increases acid secretion and reduces gastric cancer risk in humans.
- Published
- 2019
10. A Dedicated Evolutionarily Conserved Molecular Network Licenses Differentiated Cells to Return to the Cell Cycle
- Author
-
Zhenning Wang, Mahliyah Adkins-Threats, Lukas A. Huber, Nicholas O. Davidson, Deborah C. Rubin, Dongkook Park, Jianyun Lu, Valeria Cavalli, Charles J. Cho, Jeffrey W. Brown, Ilja Vietor, Marcus Mahar, Zhi Feng Miao, Jing Xu Sun, Joseph Burclaff, Mark A. Lewis, Susan Kennedy, and Jason C. Mills
- Subjects
Cellular differentiation ,Regulator ,mTORC1 ,Mechanistic Target of Rapamycin Complex 1 ,Biology ,Article ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,0302 clinical medicine ,Organelle ,Animals ,Molecular Biology ,Cell Proliferation ,030304 developmental biology ,0303 health sciences ,Cell growth ,Regeneration (biology) ,Cell Cycle ,Cell Differentiation ,Cell Biology ,Cell cycle ,biology.organism_classification ,Cell biology ,Cell Transdifferentiation ,Schizosaccharomyces pombe ,biological phenomena, cell phenomena, and immunity ,Licensure ,Cell Division ,030217 neurology & neurosurgery ,Developmental Biology - Abstract
Differentiated cells can re-enter the cell cycle to repair tissue damage via a series of discrete morphological and molecular stages coordinated by the cellular energetics regulator mTORC1. We previously proposed the term "paligenosis" to describe this conserved cellular regeneration program. Here, we detail a molecular network regulating mTORC1 during paligenosis in both mouse pancreatic acinar and gastric chief cells. DDIT4 initially suppresses mTORC1 to induce autodegradation of differentiated cell components and damaged organelles. Later in paligenosis, IFRD1 suppresses p53 accumulation. Ifrd1-/- cells do not complete paligenosis because persistent p53 prevents mTORC1 reactivation and cell proliferation. Ddit4-/- cells never suppress mTORC1 and bypass the IFRD1 checkpoint on proliferation. Previous reports and our current data implicate DDIT4/IFRD1 in governing paligenosis in multiple organs and species. Thus, we propose that an evolutionarily conserved, dedicated molecular network has evolved to allow differentiated cells to re-enter the cell cycle (i.e., undergo paligenosis) after tissue injury. VIDEO ABSTRACT.
- Published
- 2020
11. Long non-coding RNA AB007962 is downregulated in gastric cancer and associated with poor prognosis
- Author
-
Jiajun Wang, Jing‑Xu Sun, Zhenning Wang, Peng Gao, Bin Ma, Yu‑Chong Yang, Xiao‑Wan Chen, and Yong‑Xi Song
- Subjects
0301 basic medicine ,Cancer Research ,Oncogene ,Cell ,Articles ,Cell cycle ,Biology ,Molecular medicine ,Long non-coding RNA ,03 medical and health sciences ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,Cancer research ,medicine ,Clinical significance ,Gene ,Survival analysis - Abstract
A number of previous studies have reported that numerous long non-coding RNAs (lncRNAs) are dysregulated in gastric cancer (GC) and are involved in a series of biological and pathological processes. Total RNA was extracted from the cancerous tissues and matched normal adjacent tissues (NATs) of 96 patients with GC. The expression level of AB007962, a novel lncRNA, was determined by reverse transcription-quantitative polymerase chain reaction. The association between AB007962 expression levels and clinicopathological features were analyzed. Kaplan-Meier curves were also constructed in order to evaluate prognosis. Finally, publicly accessible data from The Cancer Genome Atlas was used to further verify the expression levels and clinical significance of AB007962. In conclusion, it was determined that the expression level of AB007962 was significantly reduced, compared with matched NATs in GC tissues (P=0.003). Survival analysis indicated that patients with intestinal-type GC with a reduced expression of AB007962 had a reduced prognosis, compared with those with an increased expression. AB007962 may be involved in the progression of GC and act as a novel prognostic biomarker for patients with GC, particularly in intestinal-type GC.
- Published
- 2015
12. [Research on ground scenery spectral radiation source with tunable spectra]
- Author
-
Jin-rong, Xiang, Jian-wei, Ren, Bao-yong, Li, Zhi, Wan, Ze-xun, Liu, Hong-xing, Liu, Xian-sheng, Li, and Jing-xu, Sun
- Abstract
A spectrum-tunable ground scenery spectrum radiation source, using LEDs and bromine tungsten lamp as luminescence media, was introduced. System structure and control of the spectrum radiation source was expounded in detail. In order to simulate various ground scenery spectrum distribution with different shapes, a ground scenery spectral database was established in the control system. An improved genetic algorithm was proposed, and a large number of ground scenery spectra were produced by the simulator. Spectral similarity and the average spectral matching error of several typical ground scenery spectra were further analyzed. Spectral similarity of red bands, green bands, blue bands and near-infrared spectral band also was discussed. When the radiance of the target was 50 W x (m2 x sr)(-1), the average spectral matching error was less than 10% and spectral similarity was greater than 0.9, up to 0.983. Spectral similarity of red band, green band, blue band and near-infrared band (especially green band and near-infrared band) was less than that of full-band. Compared with blue band and red band, spectral similarity of green band and near-infrared band low-amplitude maximum can rearch 50%. Ground scenery spectrum radiation source can be used as radiometric calibration source for optical remote sensor, and calibration error, which is caused by objectives and calibration sources spectral mismatch, can be effectively reduced.
- Published
- 2015
13. Which is better for gastric cancer patients, perioperative or adjuvant chemotherapy: a meta-analysis.
- Author
-
Jun-hua Zhao, Peng Gao, Yong-xi Song, Jing-xu Sun, Xiao-wan Chen, Bin Ma, Yu-chong Yang, Zhen-ning Wang, Zhao, Jun-Hua, Gao, Peng, Song, Yong-Xi, Sun, Jing-Xu, Chen, Xiao-Wan, Ma, Bin, Yang, Yu-Chong, and Wang, Zhen-Ning
- Subjects
STOMACH cancer treatment ,META-analysis ,CANCER chemotherapy ,STOMACH cancer patients ,PERIOPERATIVE care ,FLUOROPYRIMIDINES ,THERAPEUTICS ,ANTINEOPLASTIC agents ,COMBINED modality therapy ,STOMACH tumors ,SYSTEMATIC reviews - Abstract
Background: The preferred chemotherapy method for gastric cancer continues to be matter of debate. We performed a meta-analysis to comparing prognosis and safety between perioperative chemotherapy and adjuvant chemotherapy to identify the better chemotherapy option for gastric cancer.Methods: We searched the PubMed, EMBASE, Cochrane Library, and Ovid databases for eligible studies until February 2016. The main endpoints were prognostic value (hazard ratio [HR] for overall survival [OS] and 1-, 2-, 3-, and 5-year survival rate), response rate of chemotherapy, radical resection rate, post-operative complication rate, and adverse effects of chemotherapy.Results: Five randomized controlled trials and six clinical controlled trials involving 1,240 patients were eligible for analysis. Compared with the adjuvant chemotherapy group, the perioperative chemotherapy group had significantly better prognosis (HR, 0.74; 95 % CI, 0.61 to 0.89; P < 0.01). The difference between the two groups remained significant in the studies that used combination chemotherapy as the neoadjuvant chemotherapy regimen (HR, 0.59; 95 % CI, 0.46 to 0.76; P < 0.01) but were not significant in the studies that used fluoropyrimidine monotherapy (HR, 0.93; 95 % CI, 0.56 to 1.55; P = 0.84). Furthermore, the two groups showed no significant differences in the post-operative complication rates (relative risk, 0.98; 95 % CI, 0.63 to 1.51; P = 0.91) or adverse effects of chemotherapy (P > 0.05 for all adverse effects).Conclusion: Perioperative chemotherapy showed improved survival compared to adjuvant chemotherapy for gastric cancer. In addition, combination chemotherapy resulted in better survival compared to monotherapy in the neoadjuvant chemotherapy regimens. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
14. Clinicopathologic and Prognostic Value of Serum Carbohydrate Antigen 19-9 in Gastric Cancer: A Meta-Analysis.
- Author
-
Yong-xi Song, Xuan-zhang Huang, Peng Gao, Jing-xu Sun, Xiao-wan Chen, Yu-chong Yang, Cong Zhang, Hong-peng Liu, Hong-chi Wang, and Zhen-ning Wang
- Subjects
CA 19-9 test ,BLOOD serum analysis ,STOMACH cancer ,DISEASE incidence ,META-analysis ,PROGNOSIS - Abstract
The clinical value of carbohydrate antigen (CA) 19-9 in gastric cancer is controversial. We evaluated the clinicopathologic and prognostic value of CA 19-9 in gastric cancer. Methods. A literature search was conducted in PubMed and Embase databases. Odds ratios (ORs), risk ratios (RR), hazard ratios (HRs), and 95% confidence intervals (CIs) were used as effect measures. Results. Thirty-eight studies were included. Results showed that there were significant differences in the incidence of high CA 19-9 levels between stages III/IV and I/II groups (OR = 3.36; 95% CI = 2.34-4.84), the pT3/T4 and pT1/T2 groups (OR = 2.40; 95% CI = 1.60-3.59), the lymph node-positive and node-negative groups (OR = 2.91; 95% CI = 2.21-3.84), the metastasis-positive and metastasis-negative groups (OR = 2.76; 95% CI = 1.12-6.82), and vessel invasion-positive and invasion-negative groups (OR = 1.66; 95% CI = 1.11-2.48). Moreover, CA 19-9 was significantly associated with poor overall survival (HR = 1.83; 95% CI = 1.56-2.15), disease-free survival (HR = 1.85; 95% CI = 1.16-2.95), and disease-specific survival (HR = 1.33; 95% CI = 1.10-1.60) in gastric cancer. Conclusions. Our meta-analysis showed that CA 19-9 indicates clinicopathologic characteristics of gastric cancer and is associated with a poor prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
15. Which is the best postoperative chemotherapy regimen in patients with rectal cancer after neoadjuvant therapy?
- Author
-
Peng Gao, Yong-xi Song, Jing-xu Sun, Xiao-wan Chen, Ying-ying Xu, Jun-hua Zhao, Xuan-zhang Huang, Hui-mian Xu, and Zhen-ning Wang
- Subjects
POSTOPERATIVE care ,CANCER chemotherapy ,RECTAL cancer patients ,RECTAL cancer treatment ,OXALIPLATIN ,FLUOROURACIL ,THERAPEUTICS - Abstract
Background There is no general agreement about whether patients who have already received neoadjuvant chemoradiotherapy need further postoperative chemotherapy based on 5-fluorouracil(5-FU) or 5-FU plus oxaliplatin. Methods Medicare beneficiaries from 1992 to 2008 with Union for International Cancer Control ypStages I to III primary carcinoma of the rectum who underwent 5-FU-based neoadjuvant chemoradiotherapy and surgery for curative intent were identified through the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database. A Cox proportional hazards model and propensity score-matched techniques were used to evaluate the effect of treatment on survival. Results For patients with resected rectal cancer who have already received 5-FU-based neoadjuvant chemoradiotherapy, postoperative 5-FU-based chemotherapy did not prolong cancer-specific survival (CSS) in ypStage I (P = 0.960) and ypStage II (P = 0.134); however, it significantly improved the CSS in ypStage III (hazard ratio = 1.547, 95% CI = 1.101-2.173, P = 0.012). No significant differences in survival between the 5-FU group and oxaliplatin group were observed. Conclusions For patients with resected rectal cancer who have already received 5-FU-based neoadjuvant chemoradiotherapy, postoperative 5-FU-based chemotherapy prolongs the CSS of groups in ypStage III. Adding oxaliplatin to fluoropyrimidines in the postoperative chemotherapy did not improve the CSS for patients who received neoadjuvant chemoradiotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
16. Fast-track surgery versus traditional perioperative care in laparoscopic colorectal cancer surgery: a meta-analysis.
- Author
-
Jun-hua Zhao, Jing-xu Sun, Peng Gao, Xiao-wan Chen, Yong-xi Song, Xuan-zhang Huang, Hui-mian Xu, and Zhen-ning Wang
- Subjects
- *
COLON cancer treatment , *PROCTOLOGY , *LAPAROSCOPY , *META-analysis , *RANDOMIZED controlled trials - Abstract
Background: Both laparoscopic and fast-track surgery (FTS) have shown some advantages in colorectal surgery. However, the effectiveness of using both methods together is unclear. We performed this meta-analysis to compare the effects of FTS with those of traditional perioperative care in laparoscopic colorectal cancer surgery. Methods: We searched the PubMed, EMBASE, Cochrane Library, and Ovid databases for eligible studies until April 2014. The main end points were the duration of the postoperative hospital stay, time to first flatus after surgery, time of first bowel movement, total postoperative complication rate, readmission rate, and mortality. Results: Five randomized controlled trials and 5 clinical controlled trials with 1,317 patients were eligible for analysis. The duration of the postoperative hospital stay (weighted mean difference [WMD], -1.64 days; 95% confidence interval [CI], -2.25 to -1.03; p < 0.001), time to first flatus (WMD, -0.40 day; 95% CI, -0.77 to -0.04; p = 0.03), time of first bowel movement (WMD, -0.98 day; 95% CI, -1.45 to -0.52; p < 0.001), and total postoperative complication rate (risk ratio [RR], 0.67; 95% CI, 0.56-0.80; p < 0.001) were significantly reduced in the FTS group. No significant differences were noted in the readmission rate (RR, 0.64; 95% CI, 0.41-1.01; p = 0.06) or mortality (RR, 1.55; 95% CI, 0.42-5.71; p = 0.51). Conclusion: Among patients undergoing laparoscopic colorectal cancer surgery, FTS is associated with a significantly shorter postoperative hospital stay, more rapid postoperative recovery, and, notably, greater safety than is expected from traditional care. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
17. Is the prediction of prognosis not improved by the seventh edition of the TNM classification for colorectal cancer? Analysis of the surveilla006Ece, epidemiology, and end results (SEER) database.
- Author
-
Peng Gao, Yong-xi Song, Zhen-ning Wang, Ying-ying Xu, Lin-lin Tong, Jing-xu Sun, Miao Yu, and Hui-mian Xu
- Subjects
PROGNOSIS ,COLON cancer ,EPIDEMIOLOGY ,STANDARD deviations - Abstract
Background: Whether the 7th edition of American Joint Committee on Cancer (AJCC) TNM staging system (AJCC-7) is a successful revision remains debatable. We aimed to compare the predictive capacity of the AJCC-7 for colorectal cancer with the 6th edition of the AJCC TNM staging system (AJCC-6). Methods: The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) dataset consisting of 158,483 records was used in this study. We evaluated the predictive capacity of the two editions of the staging system using Harrell's C index and Bayesian Information Criterion (BIC). Results: There was a significant prognostic difference between patients at stage IIB and IIC (P < 0.001). Stage III patients with similar prognoses were adequately sub-grouped in the same stage according to AJCC-7. The Harrell's C index revealed a value of 0.7692 for AJCC-7, which was significantly better than 0.7663 for AJCC-6 (P < 0.001). BIC analysis provided consistent results (P < 0.001). Conclusions: This study demonstrates that AJCC-7 is superior to the AJCC-6 staging system in predictive ca [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.